dPD - 1 hCD19CART cells treatment of refractory, aggressive non-hodgkin's lymphoma (NHL), a safety and efficacy clinical trial

Trial Profile

dPD - 1 hCD19CART cells treatment of refractory, aggressive non-hodgkin's lymphoma (NHL), a safety and efficacy clinical trial

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=4) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 09 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top